Tubastatin A Hydrochloride_1310693-92-5_DataSheet_MedChemExpress
QIAGEN Endotoxin Removal Solution说明书
Endotoxin Removal Solution Catalog Number E4274Product DescriptionEndotoxins are lipopolysaccharides (LPS), a major component of the Gram-negative bacterial cell wall, and are commonly found as contaminants in plasmid DNA preparations from E. coli. Endotoxins are large, negatively charged molecules that co-purify with DNA on ion exchange and size exclusion columns and in CsCl banding. Endotoxins are extremely potent stimulators of the mammalian immune system and are toxic to primary cells and to animals. The endotoxin toxicity is an obstacle to in vitro and in vivo transfection experiments.Non-ionic detergents, traditionally used for separation of integral membrane proteins,1 can be utilized for removal of endotoxins from DNA solutions by phase separation.2The solubility behavior of a detergent in a dilute, aqueous solution at physiological salt and pH conditions is strongly dependent upon the temperature of the solution. At low temperatures, the detergent forms a clear, micellar solution, but above the cloud point temperature, the micelles form larger, turbid aggregates and ultimately fuse to form a separate phase. The lower phase is detergent-enriched and the detergent-depleted upper phase contains detergent at a concentration slightly above the critical micellar concentration (CMC). Amphiphilic and hydrophobic molecules associated with the micelles of the detergent will aggregate within the detergent-enriched phase, while the soluble, hydrophilic molecules will remain in the detergent-depleted upper phase.Extraction of endotoxin contaminated DNA solutions with the appropriate non-ionic detergent will separate the hydrophilic DNA from the amphiphilic endotoxin. The amphiphilic endotoxin will associate with the lower phase, while the DNA will remain in the upper, detergent-depleted phase.2Reagents and equipment required, but not provided • Water, Molecular Biology Reagent, Catalog Number W4502• E-TOXATE® Water, Catalog Number 2107, or Tris-EDTA (TE) buffer 100×, Catalog NumberT9285• DNA solution (0.5 ml), ~ 1 mg/ml in E-TOXATE®Water or TE buffer• 3 M sodium acetate solution, pH 7.5.• 2-Propanol, Catalog Number I9516, or Ethanol, 190 proof, Catalog Number E7148; 200 proof, CatalogNumber E7023• 70% Ethanol• E-TOXATE®reagents Kits, Catalog Numbers 210A1, 210B1 or 210C1• Ice bucket• Heat block or incubator at 37 °C• Microcentrifuge at room temperature• 1.5 or 2 ml sterile microcentrifuge tubes• Endotoxin-free pipet tips (40-200 µl, 200-1000 µl) Precautions and DisclaimerThis product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.StorageStore at room temperature.Note: Removal of endotoxins from DNA preparations can be performed either during the final stage of DNApreparation, or during an earlier stage.Procedures for Endotoxin RemovalDuring the final stage of DNA preparationNote: The procedure described below was performed on plasmid DNA produced in E. coli DH5α cells.• Losses of up to 50% of the DNA are expected. • Use of a DNA concentration above therecommended 1 mg/ml reduces the efficiency ofthe procedure.1. Pipette 500 µl of the DNA solution into a sterilemicrocentrifuge tube.2. Add 50 µl of the 3 M sodium acetate solution to theDNA sample.3. Incubate on ice for 5 minutes.4. Add 100 µl of cold Endotoxin Removal Solution.5. Mix thoroughly and incubate on ice for 10 minutes.The solution should be light blue and clear.6. Incubate the tube at 37 °C for 20 to 30 minutes oruntil the phases separate.7. Spin for 5 minutes at 3000 x g in themicrocentrifuge. The upper phase is colorless and clear, while the lower phase is blue.8. Carefully transfer the upper phase containing theDNA to a clean microcentrifuge tube.9. Repeat steps 4 through 8 twice.10. Add 0.6× volume of 2-propanol. Mix by inversion atroom temperature and centrifuge at 15,000 x g for30 minutes at 4 °C. Alternatively, add2.5× volumes of ethanol. Incubate overnight at –20°C or 20 minutes at –70 °C and centrifuge at15,000 x g for 30 minutes at 4 °C.11. Carefully remove the supernatant12. Wash the DNA pellet twice with cold 70% ethanol.Remove the supernatant.13. Air-dry the pellet.14. Suspend the DNA in 100 µl of endotoxin free wateror TE buffer.15. Determine DNA concentration and endotoxin levelsusing endotoxin assay reagents and compare tothe starting material. During an earlier stage of DNA preparationThis procedure is based on the alkaline lysis of E. coli DH5α cells.3 The endotoxins are removed immediately after alkaline cell lysis, neutralization, and a clarification step. The resulting high salt solution is suitable for the endotoxin removal step. It is performed under “endotoxin free” conditions. The plasticware used is either sterile and disposable, or NaOH-treated. The buffers are prepared with endotoxin free water.1. Add the Endotoxin Removal Solution (0.2× volume)to the cold, crude DNA solution.2. Incubate on ice and mix occasionally by inversionto obtain a homogenous, clear blue solution3. Incubate at 37 °C for 20 to 30 minutes until thephase separation is obvious.4. Spin for 5 minutes at low speed (3000 x g) at roomtemperature.5. Transfer the upper aqueous phase to an endotoxinfree container.6. Proceed with the DNA purification by any method.Use endotoxin-free buffers and containers. References1. Bordier, C., J. Biol. Chem., 256, 1604-1607, (1981).2. Cotten, M. et al., Gene Therapy, 1, 239-246,(1994).3. Sambrook et al., Molecular Cloning, a LaboratoryManual, 2nd Ed. p. 1.38RK,PHC 09/05-1Sigma brand products are sold through Sigma-Aldrich, Inc.Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side ofthe invoice or packing slip.。
HANKS' BALANCED SALTS [HBSS] 产品说明书
![HANKS' BALANCED SALTS [HBSS] 产品说明书](https://img.taocdn.com/s3/m/181984b63086bceb19e8b8f67c1cfad6185fe96d.png)
HANKS' BALANCED SALTS [HBSS]Without calcium chloride, magnesium sulfate and sodium bicarbonate Product Number H2387Product DescriptionAlthough there have been many modifications to the original formulas in efforts to produce fully defined media, salt solutions still play an important role in tissue culture. A salt solution's basic function, to maintain the pH and osmotic balance in the medium and to provide the cells with water and essentialinorganic ions, is as valuable today as when it was first developed a century ago.Componentsg/L Potassium Chloride0.4Potassium Phosphate Monobasic 0.06(anhydrous)Sodium Chloride8.0Sodium Phosphate Dibasic(anhydrous)0.04788D -Glucose1.0Phenol Red•Na0.011Precautions and Disclaimer REAGENTFor R&D use only. Not for drug, household or other uses.Preparation InstructionsPowdered salts are hygroscopic and should beprotected from moisture. The entire contents of each package should be used immediately after opening. Preparing a concentrated salt solution is notrecommended as precipitates may form. Supplements can be added prior to filtration or introduced aseptically to sterile salt solution.1.Measure out 90% of final required volume ofwater. Water temperature should be 15-20 ˚C.2.While gently stirring the water, add the powderedmedium. Stir until dissolved. Do NOT heat. 3.Rinse original package with a small amount ofwater to remove all traces of powder. Add to solution in step 2.4.To the solution in step 3, add 0.35 g sodiumbicarbonate or 4.7 ml of sodium bicarbonatesolution [7.5%w/v] for each liter of final volume of medium being prepared. Stir until dissolved.5.While stirring, adjust the pH of the medium to 0.1-0.3 pH units below the desired pH since it may rise during filtration. The use of 1N HCl or 1N NaOH is recommended.6.Add additional water to bring the solution to finalvolume.7.Sterilize immediately by filtration using amembrane with a porosity of 0.22 microns.8.Aseptically dispense medium into sterile container. Storage and StabilityStore the dry powdered salts at 2-8 °C under dry conditions and liquid medium at 2-8 °C in the dark. Deterioration of the powdered medium may be recognized by any or all of the following: [1] color change, [2] granulation/clumping, [3] insolubility.Deterioration of the liquid medium may be recognized by any or all of the following: [1] pH change, [2] precipitate or particulates, [3] cloudy appearance [4] color change. The nature of supplements added may affect storage conditions and shelf life of the medium. Product label bears expiration date.ProcedureMaterials Required but Not Provided:Water for tissue culture [W3500]Sodium Bicarbonate [S5761] orSodium Bicarbonate Solution, 7.5% [S8761]1N Hydrochloric Acid [H9892]1N Sodium Hydroxide [S2770]Medium additives as requiredReference1.Hanks, J. (1976) Hanks' Balanced SaltSolution and pH Control. Tissue Culture Association Manual. 3, 3.Revised: March 2007Sigma-Aldrich, I nc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.。
小分子抑制剂、激动剂、拮抗剂--NF-κB信号通路
NF-κBNF-κB是一种控制DNA转录的蛋白质复合物。
NF-κB几乎存在于所有动物细胞类型中，并参与机体的炎症反应、免疫应答，能调节细胞凋亡、应激反应。
NF-κB网络由五个家族成员蛋白单体（p65 / RelA，RelB，cRel，p50和p52）组成，它们形成同源二聚体或异二聚体，其差异结合DNA并受两种途径调节：经典的NF-κB必需调节剂（NEMO）依赖性途径和非经典的NEMO非依赖性途径。
NF-κB通路的过度激活，与人类许多疾病相关，如哮喘、类风湿性关节炎、炎症性肠病、心脏与脑部疾病的炎症等。
此外，改变的NF-κB调节可能涉及其他疾病，如动脉粥样硬化和阿尔茨海默病和各种各样的人类癌症。
NF-κB通路转导过程NF-κB经典信号通路中，通过IκB蛋白降解释放NF-κB二聚体。
细胞受到胞外刺激后，信号因子与细胞膜上的受体结合，激活IκB激酶（IKK）。
IκB磷酸化后进一步泛素化，进而释放NF-κB二聚体。
NF-κB二聚体经翻译后修饰（磷酸化、乙酰化、糖基化等）激活，并转运入胞核，在核内单独或联合其他转录因子，促进基因的表达。
NF-κB非经典信号通路中，则通过p100到p52的加工处理来激活信号通路。
信号转导通过受体子集（LTβR、CD40和BR3等），激活激酶NIK，进而激活IKKα复合体，IKKα复合体再磷酸化NF-κB2 p100（C端残基）。
磷酸化后的NF-κB2 p100将自身泛素化，再经蛋白酶加工为NF-κB2 p52。
此时，在胞浆中失活的NF-κB2 p100/RelB已激活为NF-κB p52/Rel B 复合体，转运入胞核，诱导目的基因的表达。
NF-κB信号通路图按靶点分类：*HDACRG2833 1215493-56-3 HDAC1 60 nM *NF-κB*IκB/IKK。
香叶木素葡萄糖醛酸苷
香叶木素葡萄糖醛酸苷
香叶木素葡萄糖醛酸苷，也被称为Diosmetin 7-O-β-D-glucuronide，是一种具有化学性质的物质。
以下是关于香叶木素葡萄糖醛酸苷的更多信息：
1. 化学性质：香叶木素葡萄糖醛酸苷的分子式为C22H20O12，分子量为476.39。
其沸点为853.6±65.0 °C。
2. 纯度：其纯度为HPLC≥98%。
3. CAS号：香叶木素葡萄糖醛酸苷的CAS号为35110-20-4。
4. 保存方式：该物质应保存在2-8°C的环境中。
5. 外观：其外观为品牌为源叶，货号为B74690-10mg，产品包装为10mg，上海源叶生物科技有限公司出品。
以上信息仅供参考，如需获取更具体的信息，建议查阅相关的资料或咨询专业人士。
REACHSVHC清单181项英文版
REACHSVHC清单181项英文版REACH SVHC FinderREACH SVHC Finder is a free tool developed by CSP to help you quickly search if a chemical substance belongs to Substance of Very High Concern (SVHC)under EU REACH regulation or not and whether it is subject to REACH authorization. It allows you to search both SVHC list and authorization list at the same time.SVHCs which have been added to authorization list cannot be placed on the market or used after sunset date, unless an authorization is granted for their specific use, or the use is exempted from authorisation. More info about REACH SVHC and your obligations can be found here. Please also try another useful tool called REACH Restricted Substances Finder (RRS Finder).Please note that the CAS no. given below is not an-exhaustive list. There are currently 181SVHCs [Updated: 16 Jan 2018].Index Substance Name EC No. CAS No. InclusionDate(M/D/Y)If OnAuthorizationList andSunset Date?181 Benz[a]anthracene 200-280-6 56-55-3,1718-53-21/15/2018180 Cadmium carbonate 208-168-9 513-78-0 1/15/2018 179 Cadmium hydroxide 244-168-5 21041-95-2 1/15/2018 178 Cadmium nitrate 233-710-6 10022-68-1,10325-94-71/15/2018177 Chrysene 205-923-4 218-01-9, 1719-03-51/15/2018176 Dodecachloropentacyclo[12.2.1 .16,9.02,13.05,10]octadeca-7,15-diene ("Dechlorane Plus"?)- - 1/15/2018175 Reaction products of1,3,4-thiadiazolidine-2,5-dit hione, formaldehyde and4-heptylphenol, branched and linear (RP-HP)- - 1/15/2018174 Perfluorohexane-1-sulphonic acid and its salts (PFHxS)- - 7/7/2017173 4,4'-isopropylidenediphenol (bisphenol A)201-245-8 80-05-7 1/12/2017172 nonadecafluorodecanoic acid (PFDA) and its sodium and ammonium salts206-400-3 335-76-2 1/12/2017 171 4-heptylphenol, branched and linear (4-HPbl)- - 1/12/2017170 p-(1,1-dimethylpropyl)phenol (PTAP)201-280-9 80-46-6 1/12/2017Index Substance Name EC No. CAS No. Date(M/D/Y) Authorization List and Sunset Date?169 Benzo[def]chrysene 200-028-5 50-32-8 6/20/2016 168 Nitrobenzene 202-716-0 98-95-3 12/17/2015167 2,4-di-tert-butyl-6-(5-chlorobenzotriazol-2-yl)phenol(UV-327)223-383-8 3864-99-1 12/17/2015166 2-(2H-benzotriazol-2-yl)-4-(tert-butyl)-6-(sec-butyl)phenol (UV-350)253-037-1 36437-37-3 12/17/2015165 1,3-propanesultone 214-317-9 1120-71-4 12/17/2015 164 Perfluorononan-1-oic-acid andits sodium and ammonium salts206-801-3375-95-1,21049-39-8,4149-60-412/17/2015163 1,2-benzenedicarboxylic acid,di-C6-10-alkyl esters;1,2-benzenedicarboxylic acid,mixed decyl and hexyl and octyldiesters with ≥ 0.3% ofdihexyl phthalate (EC No.201-559-5)271-094-0,272-013-168515-51-5,68648-93-16/15/2015162 5-sec-butyl-2-(2,4-dimethylcy clohex-3-en-1-yl)-5-methyl-1,3-dioxane [1],5-sec-butyl-2-(4,6-dimethylcy clohex-3-en-1-yl)-5-methyl-1,3-dioxane [2] [covering any ofthe individual stereoisomers of [1] and [2] or any combination thereof]6/15/2015161 Bis (2-ethylhexyl)phthalate (DEHP)204-211-0 117-81-72014/12/17;2008/10/28Yes,02/21/2015160 2-(2H-benzotriazol-2-yl)-4,6- ditertpentylphenol (UV-328)247-384-8 25973-55-1 12/17/2014 159 2-benzotriazol-2-yl-4,6-di-te rt-butylphenol (UV-320)223-346-6 3846-71-7 12/17/2014 158 2-ethylhexyl10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate (DOTE)239-622-4 15571-58-1 12/17/2014157 Cadmium fluoride 232-222-0 7790-79-6 12/17/2014Index Substance Name EC No. CAS No. Date(M/D/Y) Authorization List and Sunset Date?156 Cadmium sulphate 233-331-6 10124-36-4,31119-53-612/17/2014155 reaction mass of 2-ethylhexyl10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate and 2-ethylhexyl10-ethyl-4-[[2-[(2-ethylhexyl)oxy]-2-oxoethyl]thio]-4-octyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate (reactionmass of DOTE and MOTE)12/17/2014154 1,2-Benzenedicarboxylic acid,dihexylester, branched andlinear271-093-5 68515-50-4 6/16/2014153 Cadmium chloride 233-296-7 10108-64-2 6/16/2014152 Sodium perborate,perboricacid, sodium salt239-172-9,234-390-06/16/2014151 Sodium peroxometaborate 231-556-4 7632-4-4, 6/16/2014 150 Cadmium sulphide 215-147-8 1306-23-612/16/2013 149 Dihexyl phthalate 201-559-5 84-75-3 12/16/2013148 Disodium3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis(4-aminonaphthalene-1-sulphonate) (C.I.Direct Red 28)209-358-4 573-58-0 12/16/2013147 Disodium4-amino-3-[[4'-[(2,4-diaminophenyl)azo][1,1'-biphenyl]-4-yl]azo]-5-hydroxy-6-(phenylazo)naphthalene-2,7-disulphonate (C.I.Direct Black 38)217-710-3 1937-37-7 12/16/2013146 Imidazolidine-2-thione(2-imidazoline-2-thiol)202-506-9 96-45-7 12/16/2013145 Lead di(acetate) 206-104-4 301-04-2 12/16/2013 144 Trixylyl phosphate 246-677-8 25155-23-1 12/16/2013 143 4-Nonylphenol, branched andlinear, ethoxylated[substances with a linearand/or branched alkyl chain6/20/2013Yes,01/04/2021Index Substance Name EC No. CAS No. Date(M/D/Y) Authorization List and Sunset Date?with a carbon number of 9 covalently bound in position 4 to phenol, ethoxylated covering UVCB- and well-defined substances, polymers and homologues, which include any of the individual isomersand/or combinations thereof]142 Ammoniumpentadecafluorooctanoate(APFO)223-320-4 3825-26-1 6/20/2013141 Cadmium 231-152-8 7440-43-9 6/20/2013 140 Cadmium oxide 215-146-2 1306-19-0 6/20/2013139 Dipentyl phthalate (DPP) 205-017-9 131-18-0 6/20/2013 Yes,07/04/2020138 Pentadecafluorooctanoic acid(PFOA)206-397-9 335-67-1 6/20/2013137 1,2-Benzenedicarboxylic acid,dipentylester, branched andlinear284-032-2 84777-06-0 12/19/2012Yes,07/04/2020136 1,2-Diethoxyethane 211-076-1 629-14-1 12/19/2012135 1-bromopropane (n-propylbromide)203-445-0 106-94-5 12/19/2012Yes,07/04/2020134 3-ethyl-2-methyl-2-(3-methylbutyl)-1,3-oxazolidine421-150-7 143860-04-2 12/19/2012133 4,4'-methylenedi-o-toluidine 212-658-8 838-88-0 12/19/2012 132 4,4'-oxydianiline and its salts 202-977-0 101-80-4 12/19/2012131 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated [coveringwell-defined substances andUVCB substances, polymers andhomologues]12/19/2012130 4-Aminoazobenzene 200-453-6 60-09-3 12/19/2012129 4-methyl-m-phenylenediamine(toluene-2,4-diamine)202-453-1 95-80-7 12/19/2012128 4-Nonylphenol, branched andlinear [substances with alinear and/or branched alkylchain with a carbon number of 9covalently bound in position 412/19/2012Index Substance Name EC No. CAS No.Date(M/D/Y)AuthorizationList andSunset Date?to phenol, covering also UVCB- and well-defined substances which include any of the individual isomers or a combination thereof] 127 6-methoxy-m-toluidine(p-cresidine)204-419-1120-71-8 12/19/2012126 [Phthalato(2-)]dioxotrilead 273-688-5 69011-06-9 12/19/2012125 Acetic acid, lead salt, basic 257-175-3 51404-69-4 12/19/2012 124 Biphenyl-4-ylamine 202-177-1 92-67-1 12/19/2012 123Bis(pentabromophenyl) ether (decabromodiphenyl ether) (DecaBDE)214-604-9 1163-19-5 12/19/2012122Cyclohexane-1,2-dicarboxylic anhydride [1],cis-cyclohexane-1,2-dicarboxy lic anhydride [2],trans-cyclohexane-1,2-dicarbo xylic anhydride [3] [The individual cis- [2] and trans- [3] isomer substances and all possible combinations of the cis- and trans-isomers [1] are covered by this entry] 201-604-9, 236-086-3, 238-009-9 85-42-7, 13149-00-3, 14166-21-312/19/2012 121 Diazene-1,2-dicarboxamide(C,C`-azodi(formamide)) (ADCA)204-650-8123-77-3 12/19/2012120 Dibutyltin dichloride (DBTC) 211-670-0 683-18-1 12/19/2012 119 Diethyl sulphate 200-589-6 64-67-5 12/19/2012 118 Diisopentylphthalate210-088-4605-50-5 12/19/2012Yes,07/04/2020117 Dimethyl sulphate 201-058-1 77-78-1 12/19/2012 116 Dinoseb(6-sec-butyl-2,4-dinitropheno l)201-861-7 88-85-712/19/2012115 Dioxobis(stearato)trilead 235-702-8 12578-12-0 12/19/2012 114 Fatty acids, C16-18, lead salts 292-966-7 91031-62-8 12/19/2012 113 Furan 203-727-3 110-00-9 12/19/2012 112 Henicosafluoroundecanoic acid 218-165-4 2058-94-8 12/19/2012 111Heptacosafluorotetradecanoicacid206-803-4376-06-712/19/2012Index Substance Name EC No. CAS No.Date(M/D/Y)AuthorizationList andSunset Date?110Hexahydromethylphthalic anhydride [1],Hexahydro-4-methylphthalic anhydride [2],Hexahydro-1-methylphthalic anhydride [3], Hexahydro-3-methylphthalic anhydride [4] [The individual isomers [2], [3] and [4] (including their cis- and trans- stereo isomeric forms) and all possible combinations of the isomers [1] are covered by this entry]247-094-1, 243-072-0, 256-356-4, 260-566-1 25550-51-0,19438-60-9,48122-14-1, 57110-29-912/19/2012109 Lead bis(tetrafluoroborate) 237-486-0 13814-96-5 12/19/2012 108 Lead cyanamidate 244-073-9 20837-86-9 12/19/2012 107 Lead dinitrate 233-245-9 10099-74-8 12/19/2012 106 Lead monoxide (lead oxide) 215-267-0 1317-36-8 12/19/2012 105 Lead oxide sulfate 234-853-7 12036-76-9 12/19/2012 104 Lead titanium trioxide 235-038-9 12060-00-3 12/19/2012 103 Lead titanium zirconium oxide 235-727-4 12626-81-2 12/19/2012 102 Methoxyacetic acid 210-894-6 625-45-6 12/19/2012 101 Methyloxirane (Propyleneoxide)200-879-275-56-9 12/19/2012100 N,N-dimethylformamide 200-679-5 68-12-2 12/19/2012 99 N-methylacetamide 201-182-6 79-16-312/19/201298 N-pentyl-isopentylphthalate776297-69-9 12/19/2012Yes,07/04/202097 o-aminoazotoluene 202-591-2 97-56-3 12/19/2012 96 o-Toluidine 202-429-0 95-53-4 12/19/2012 95 Orange lead (lead tetroxide) 215-235-6 1314-41-6 12/19/2012 94 Pentacosafluorotridecanoicacid276-745-272629-94-8 12/19/2012 93 Pentalead tetraoxide sulphate 235-067-7 12065-90-6 12/19/2012 92Pyrochlore, antimony leadyellow232-382-18012-00-8 12/19/201291 Silicic acid (H2Si2O5), barium salt (1:1), lead-doped [withlead (Pb) content above the applicable generic272-271-568784-75-8 12/19/2012Index Substance Name EC No. CAS No. Date(M/D/Y) Authorization List and Sunset Date?concentration limit for ’toxicity for reproduction’Repr. 1A (CLP) or category 1(DSD),the substance is a memberof the group entry of leadcompounds, with index number082-001-00-6 in Regulation (EC)No 1272/2008]90 Silicic acid, lead salt 234-363-3 11120-22-2 12/19/201289 Sulfurous acid, lead salt,dibasic263-467-1 62229-08-7 12/19/201288 Tetraethyllead 201-075-4 78-00-2 12/19/2012 87 Tetralead trioxide sulphate 235-380-9 12202-17-4 12/19/2012 86 Tricosafluorododecanoic acid 206-203-2 307-55-1 12/19/201285 Trilead bis(carbonate)dihydroxide215-290-6 1319-46-6 12/19/201284 Trilead dioxide phosphonate 235-252-2 12141-20-7 12/19/201283 1,2-bis(2-methoxyethoxy)ethane (TEGDME,triglyme)203-977-3 112-49-2 6/18/2012 82 1,2-dimethoxyethane,ethylene glycol dimethyl ether (EGDME) 203-794-9 110-71-4 6/18/2012 81 1,3,5-Tris(oxiran-2-ylmethyl)-1,3,5-triazinane-2,4,6-trione (TGIC)219-514-3 2451-62-9 6/18/2012 80 1,3,5-tris[(2S and2R)-2,3-epoxypropyl]-1,3,5-tr iazine-2,4,6-(1H,3H,5H)-trione (β-TGIC)423-400-0 59653-74-6 6/18/2012 79 4,4'-bis(dimethylamino)-4''-( methylamino)trityl alcohol [with ≥ 0.1% of Michler'sketone (EC No. 202-027-5) or Michler's base (EC No.202-959-2)]209-218-2 561-41-1 6/18/2012 78 4,4'-bis(dimethylamino)benzop henone (Michler’s ketone)202-027-5 90-94-8 6/18/201277 [4-[4,4'-bis(dimethylamino) benzhydrylidene]cyclohexa-2,5-dien-1-ylidene]dimethylammon ium chloride (C.I. Basic Violet208-953-6 548-62-9 6/18/2012Index Substance Name EC No. CAS No.Date(M/D/Y)AuthorizationList andSunset Date?3) [with ≥ 0.1% of Michler's ketone (EC No. 202-027-5) or Michler's base (EC No. 202-959-2)]76[4-[[4-anilino-1-naphthyl][4-(dimethylamino)phenyl]methyle ne]cyclohexa-2,5-dien-1-ylide ne] dimethylammonium chloride(C.I. Basic Blue 26) [with ≥ 0.1% of Michler's ketone (EC No. 202-027-5) or Michler's base (EC No. 202-959-2)] 219-943-6 2580-56-5 6/18/201275 Diboron trioxide 215-125-8 1303-86-2 6/18/2012 74 Formamide 200-842-0 75-12-7 6/18/2012 73 Lead(II) bis(methanesulfonate) 401-750-5 17570-76-2 6/18/2012 72 N,N,N',N'-tetramethyl-4,4'-methylenedianiline (Michler ’s base) 202-959-2 101-61-16/18/201271α,α-Bis[4-(dimethylamino)phenyl]-4(phenylamino)naphthalene-1-methanol (C.I. Solvent Blue 4) [with ≥ 0.1% of Michler's ketone (EC No. 202-027-5) or Michler's base (EC No. 202-959-2)] 229-851-8 6786-83-0 6/18/201270 1,2-Dichloroethane203-458-1107-06-2 12/19/2011Yes,11/22/201769 2,2'-dichloro-4,4'-methylenedianiline (MOCA)202-918-9101-14-4 12/19/2011Yes,11/22/201768 2-Methoxyaniline,o-Anisidine 201-963-1 90-04-0 12/19/2011674-(1,1,3,3-tetramethylbutyl)phenol205-426-2140-66-912/19/2011Yes,01/04/202166Aluminosilicate Refractory Ceramic Fibres are fibres covered by index number650-017-00-8 in Annex VI, part 3, table 3.1 of Regulation (EC) No 1272/2008 of the European12/19/2011Index Substance Name EC No. CAS No.Date(M/D/Y)AuthorizationList andSunset Date?Parliament and of the Council of 16 December 2008 onclassification, labelling and packaging of substances and mixtures, and fulfil the three following conditions: a) oxides of aluminium and silicon are the main components present (in the fibres) within variableconcentration ranges b) fibres have a length weightedgeometric mean diameter less two standard geometric errors of 6 or less micrometres (μm) c) alkaline oxide and alkali earth oxide (Na2O+K2O+CaO+MgO+BaO) content less or equal to 18% by weight65 Arsenic acid231-901-9 7778-39-4 12/19/2011Yes,08/22/2017 64 Bis(2-methoxyethyl) ether203-924-4111-96-6 12/19/2011Yes,08/22/2017 63 Bis(2-methoxyethyl) phthalate 204-212-6 117-82-8 12/19/2011Yes,07/04/202062 Calcium arsenate231-904-5 7778-44-1 12/19/201161 Dichromium tris(chromate)246-356-224613-89-6 12/19/2011Yes,01/22/2019 60 Formaldehyde, oligomericreaction products with aniline 500-036-125214-70-4 12/19/2011Yes,08/22/201759 Lead diazide, Lead azide 236-542-1 13424-46-9 12/19/2011 58 Lead dipicrate 229-335-2 6477-64-1 12/19/2011 57 Lead styphnate 239-290-0 15245-44-0 12/19/2011 56 N,N-dimethylacetamide 204-826-4 127-19-5 12/19/201155 Pentazinc chromateoctahydroxide 256-418-049663-84-5 12/19/2011Yes,01/22/201954 Phenolphthalein 201-004-7 77-09-8 12/19/2011 53 Potassiumhydroxyoctaoxodizincatedichro mate234-329-8 11103-86-9 12/19/2011Yes, 01/22/2019 52Trilead diarsenate 222-979-53687-31-8 12/19/2011Index Substance Name EC No. CAS No. Date(M/D/Y) Authorization List and Sunset Date?51 Zirconia AluminosilicateRefractory Ceramic Fibres arefibres covered by index number650-017-00-8 in Annex VI, part3, table 3.1 of Regulation (EC)No 1272/2008 of the EuropeanParliament and of the Council of16 December 2008 onclassification, labelling andpackaging of substances andmixtures, and fulfil the threefollowing conditions: a) oxidesof aluminium, silicon andzirconium are the maincomponents present (in thefibres) within variableconcentration ranges b) fibreshave a length weightedgeometric mean diameter lesstwo standard geometric errorsof 6 or less micrometres (μm).c) alkaline oxide and alkaliearth oxide(Na2O+K2O+CaO+MgO+BaO) contentless or equal to 18% by weight12/19/201150 Cobalt dichloride 231-589-4 7646-79-9 2011/06/20 - 2008/10/2849 1,2,3-trichloropropane 202-486-1 96-18-4 6/20/2011 48 1,2-Benzenedicarboxylic acid,di-C6-8-branched alkyl esters,C7-rich276-158-1 71888-89-6 6/20/2011Yes,07/04/202047 1,2-Benzenedicarboxylic acid,di-C7-11-branched and linearalkyl esters271-084-6 68515-42-4 6/20/201107/04/202046 1-Methyl-2-pyrrolidone (NMP) 212-828-1 872-50-4 6/20/2011 45 2-Ethoxyethyl acetate 203-839-2 111-15-9 6/20/201144 Hydrazine 206-114-9 302-01-2,7803-57-86/20/201143 Strontium chromate 232-142-6 7789-6-2, 6/20/2011 Yes,Index Substance Name EC No. CAS No.Date(M/D/Y)AuthorizationList andSunset Date? 01/22/201942 2-Ethoxyethanol 203-804-1 110-80-5 12/15/2010 412-Methoxyethanol 203-713-7 109-86-412/15/201040Acids generated from chromium trioxide and their oligomers. Names of the acids and theiroligomers: Chromic acid,Dichromic acid, Oligomers of chromic acid and dichromic acid.231-801-5,236-881-57738-94-5, 13530-68-2 12/15/2010Yes,09/21/201739 Chromium trioxide 215-607-8 1333-82-0 12/15/201009/21/201738Cobalt(II) carbonate 208-169-4 513-79-1 12/15/2010 37 Cobalt(II) diacetate 200-755-8 71-48-7 12/15/2010 36 Cobalt(II) dinitrate 233-402-1 10141-05-6 12/15/2010 35 Cobalt(II) sulphate 233-334-2 10124-43-3 12/15/201034 Ammonium dichromate 232-143-1 7789-9-5, 6/18/2010Yes,09/21/201733Boric acid233-139-2, 234-343-4 10043-35-3,11113-50-1 6/18/201032Disodium tetraborate, anhydrous215-540-41303-96-4,1330-43-4, 12179-04-36/18/2010 31 Potassium chromate 232-140-5 7789-00-6 6/18/2010Yes,09/21/2017 30 Potassium dichromate 231-906-6 7778-50-9 6/18/2010Yes,09/21/2017 29 Sodium chromate 231-889-5 7775-11-3, 6/18/2010Yes,09/21/2017 28 Tetraboron disodium heptaoxide, hydrate 235-541-3 12267-73-1 6/18/201027 Trichloroethylene 201-167-4 79-01-66/18/2010Yes,04/21/201626 Acrylamide201-173-779-06-1 3/30/201025 2,4-Dinitrotoluene (2,4-DNT) 204-450-0 121-14-2 1/13/2010Yes,08/21/2015 24 Anthracene oil292-602-7 90640-80-5 1/13/2010Yes,10/04/2020 23Anthracene oil, anthracene paste292-603-290640-81-6 1/13/2010Index Substance Name EC No. CAS No.Date(M/D/Y)AuthorizationList andSunset Date?22 Anthracene oil, anthracenepaste, anthracene fraction 295-275-991995-15-2 1/13/2010 21 Anthracene oil, anthracenepaste, distn. lights295-278-591995-17-4 1/13/201020 Anthracene oil, anthracene-low 292-604-8 90640-82-71/13/201019 Diisobutyl phthalate (DIBP) 201-553-2 84-69-5 1/13/2010Yes,02/21/2015 18Lead chromate231-846-07758-97-6 1/13/2010Yes,05/21/2015 17Lead chromate molybdatesulphate red (C.I. Pigment Red 104) 235-759-9 12656-85-8 1/13/2010Yes,05/21/201516 Lead sulfochromate yellow (C.I.Pigment Yellow 34)215-693-71344-37-2 1/13/2010 Yes,05/21/2015 15 Pitch, coal tar, high temp. 266-028-2 65996-93-2 1/13/2010Yes,10/04/2020 14 Tris(2-chloroethyl)phosphate 204-118-5 115-96-8 1/13/2010Yes,08/21/2015 13 4,4'- Diaminodiphenylmethane(MDA)202-974-4101-77-9 10/28/2008Yes,08/21/2014 12 5-tert-butyl-2,4,6-trinitro-m-xylene (Musk xylene)201-329-481-15-2 10/28/2008Yes,08/21/2014 11 Alkanes, C10-13, chloro (ShortChain Chlorinated Paraffins) 287-476-585535-84-8 10/28/2008 10 Anthracene 204-371-1 120-12-7 10/28/200809 Benzyl butyl phthalate (BBP) 201-622-7 85-68-7 10/28/2008Yes,02/21/201508 Bis(tributyltin) oxide (TBTO) 200-268-0 56-35-9 10/28/200807 Diarsenic pentaoxide 215-116-9 1303-28-2 10/28/2008Yes,05/21/2015 06 Diarsenic trioxide 215-481-4 1327-53-3 10/28/2008Yes,05/21/2015 05Dibutyl phthalate (DBP)201-557-484-74-2 10/28/2008Yes,02/21/201504Hexabromocyclododecane (HBCDD) and all major diastereoisomers identified: Alpha-hexabromocyclododecane Beta-hexabromocyclododecane Gamma-hexabromocyclododecane247-148-4, 221-695-9 25637-99-4, 3194-55-6, 134237-50-6, 134237-51-7,10/28/2008Yes,08/21/2015Index Substance Name EC No. CAS No. Date(M/D/Y) Authorization List and Sunset Date?134237-52-803 Lead hydrogen arsenate 232-064-2 7784-40-9 10/28/200802 Sodium dichromate 234-190-3 7789-12-0,10588-01-910/28/2008Yes,09/21/201701 Triethyl arsenate 427-700-2 15606-95-8 10/28/2008。
亚麻籽胶结构式
亚麻籽胶结构式
分子式：C32H46O16分子量：686.6981
别名：亚麻籽提取物;2,3-双(3-甲氧基-4-羟基苄基)丁烷-1,4-二醇1,4-二葡萄糖甙;开环异落叶松酚二葡萄糖苷;亚麻木酚素;木酚素;西藏麝香;亚麻木酚素标准品;亚麻木酚素(SDG);亚麻木酚素(SDG),植物提取物,标准品,对照品;亚麻木酚素（标准品）;亚麻木酚素,亚麻木酚素对照品;亚麻木酯素;亚麻提取物亚麻木酚素;亚麻籽胶;亚麻籽提取物亚麻木酚素;2,3-双(3-甲氧基-4-羟基苄基)丁烷-1,4-二醇-1,4-二葡萄糖甙;80目;亚麻木酚素(亚麻木酯素,亚麻木脂素,开环异落叶松酚二葡萄糖苷);亚麻木脂素;亚麻木酚素亚麻籽提取物;开环异落叶松树脂酚二葡萄糖苷。
对氨基二甲基苯胺盐酸盐别名
对氨基二甲基苯胺盐酸盐别名氨基二甲基苯胺盐酸盐是一种有机化合物，其化学式为C8H12NCl，分子量164.648g/mol。
该化合物是一种白色结晶性粉末，可溶于水、醇和乙醚等有机溶剂。
在医药、染料、橡胶、电路板等领域有广泛应用。
以下是氨基二甲基苯胺盐酸盐别名：1. 2,4-Dimethylaniline hydrochloride2. 2,4-DMA HCl3. 2,4-Xylidine hydrochloride4. 1-Amino-2,4-dimethylbenzene hydrochloride5. N,N-Dimethyl-o-toluidine hydrochloride6. Benzidine yellow G hydrochloride salt7. Chrysoidine R hydrochloride8. Waxoline yellow R hydrochloride9. Oil yellow HGC hydrochloride10. C.I. Basic yellow 2 hydrochloride11. Solvent yellow 2 hydrochloride12. Acid yellow 2RL hydrochloride13. Durofix yellow 2G hydrochloride14.1-(2,4-Dimethylphenyl)ethanamine hydrochloride15. C.I. Azoic diazo component 1316. C.I. Solvent Yellow 4417. 2,4-Dimethyl-1-phenylamine monohydrochloride18. 2,4-Xylidine hydrochloride19. 2,4-Dimethylaniline hydrochloride20. 1-Amino-2,4-dimethylbenzene hydrochloride21. 1-(2,4-Dimethylphenyl) Ethanamine Hydrochloride22. N,N-Dimethyl-o-toluidine Hydrochloride23. Basic Yellow 2 Hydrochloride24. C.I Solvent Yellow 2 Hydrochloride25. Yellow 12 Hydrochloride26. Waxoline Yellow R Hydrochloride27. Oil Yellow HGC Hydrochloride28. Chrysoidine R Hydrochloride29. Acid Yellow 2RL Hydrochloride30. Durofix Yellow 2G Hydrochloride以上是氨基二甲基苯胺盐酸盐的别名，这些名字可以用于不同的行业标签或命名约定。
阿司咪唑
合成方法
合成方法
化合物(I)和碘甲烷在乙醇中回流8h，环合得到化合物(Ⅱ)。再水解脱去酯基，得到化合物(Ⅲ)。用对甲氧 基苯乙基溴进行N-烷基化，得化合物(Ⅳ)。再用对氟苄基溴烷基化，得阿司咪唑。
1. 1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮的制备
在反应瓶中加入2-羟基苯并咪唑5.0g(37.3mmol)和NaH 1.6g(53mmol)(NaH含量大约为80%,浸入矿物油中) 的DMF 100ml的悬浮液.加毕.在60ºC.(最好有N2保护)搅拌反应1h.再加入4-氟苄基氯(FBC)5.4g(37mmol),加热 ( 6 0 ºC ) 搅 拌 反 应 5 . 5 h . 冷 却 至 室 温 后 加 入 冰 水 7 0 0 m l , 用 二 氯 甲 烷 ( 5 0 0 m l × 2 ) 提 取 . 有 机 层 用 食 盐 水 洗 . 无 水 N a 2 S O 4 干燥.过滤.滤液减压浓缩.剩余物用石油醚析晶.得1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮固体8.0g,为无色 结 晶 m p 1 7 8 ~ 1 7 9 ºC , 收 率 8 8 % .
治疗措施
阿司咪唑中毒的治疗要点为： 1.大量摄入者予洗胃，后灌服活性炭和导泻。 2.对心肌抑制和Q-T间期延长者予5%碳酸氢钠250ml静注可能有效。 3.对症、支持治疗。
专家点评
专家点评
阿司咪阿司咪唑自1983年上市以来，在许多国家得到了广泛应用。国外研究显示阿司咪唑治疗荨麻疹的总有 效率为74%。国内的一项多中心双盲安慰剂对照试验表明阿司咪唑对急性荨麻疹的总有效率为82.9%，对慢性荨麻 疹的总有效率为86.0%，均显著高于安慰剂，主要不良反应为嗜睡、倦怠、口干等，连续用药3个月的患者中，半 数有食欲及体重增加。阿司咪唑的心脏毒性虽然发生率较低，但由于后果严重，已限制了它的应用。阿司咪唑为 强效和长效的H1受体拮抗剂，无中枢镇静和抗毒蕈碱样作用。代谢产物去甲阿司咪唑仍有抗胆胺作用。长期服用 可增进食欲和增加体重，服用过量可引起心脏Q-T间期延长和室性心律失常。适用于各种原因引起过敏性疾病。
阿拉丁癸二酸二丁酯产品安全技术说明书
GHS07:感叹号3成分/组成信息 3.1物 质分子式:C18H34O4； [-(CH2)4CO2(CH2)3CH3]2分子量 :314.46 g/mol成分 (单一物质)浓度癸二酸二丁酯Dibutyl sebacateCAS No. 109-43-3EC-编号203-672-598%4急救措施4.1必要的急救措施描述一般的建议请教医生。
出示此安全技术说明书给到现场的医生看。
如果吸入如果吸入,请将患者移到新鲜空气处。
如果停止了呼吸,给于人工呼吸。
请教医生。
在皮肤接触的情况下用肥皂和大量的水冲洗。
请教医生。
在眼睛接触的情况下用大量水彻底冲洗至少15分钟并请教医生。
如果误服切勿给失去知觉者从嘴里喂食任何东西。
用水漱口。
请教医生。
4.2最重要的症状和影响，急性的和滞后的据我们所知，此化学，物理和毒性性质尚未经完整的研究。
4.3及时的医疗处理和所需的特殊处理的说明和指示无数据资料5消防措施5.1灭火介质火灾特征无数据资料灭火方法及灭火剂用水雾,耐醇泡沫,干粉或二氧化碳灭火。
5.2源于此物质或混合物的特别的危害碳氧化物5.3救火人员的预防如必要的话,戴自给式呼吸器去救火。
5.4进一步的信息无数据资料6泄露应急处理6.1人员的预防,防护设备和紧急处理程序使用个人防护设备。
防止吸入蒸汽、气雾或气体。
保证充分的通风。
将人员撤离到安全区域。
6.2环境预防措施不要让产物进入下水道。
6.3抑制和清除溢出物的方法和材料用惰性吸附材料吸收并当作危险废品处理。
存放进适当的闭口容器中待处理。
6.4参考其他部分丢弃处理请参阅第13节。
7安全操作与储存7.1安全操作的注意事项避免接触皮肤和眼睛。
防止吸入蒸汽和烟雾。
一般性的防火保护措施。
7.2安全储存的条件,包括任何不兼容性贮存在阴凉处。
容器保持紧闭，储存在干燥通风处。
7.3特定用途无数据资料8接触控制/个体防护8.1控制参数最高容许浓度成分 CAS No. 值控制参数基准癸二酸二丁酯Dibutyl sebacate 109-43-3PC-TWA无数据资料 《工作场所有害因素职业接触限值》国家标准中的工作场所时间加权平均容许浓度无数据资料无数据资料 无数据资料8.2暴露控制适当的技术控制按照良好工业和安全规范操作。
执业药师药理学真题
B.水溶液呈中性 D. 可用 Vitali 反应鉴别B. 左旋体 D. 内消旋体B.与香草醛试液反应 D.Vitali 反应按题干要求在五个备选答案中选出一个最佳答案 , 最佳选择题 ．下列不属于免疫抑制药物是： 1A •巯嘌吟B •肾上腺皮质激素类C. 卡介苗 D •环磷酰胺E .环抱素2．下列不属于免疫增强药物是： A •干扰素 B •转移因子C. 左旋咪唑 D •抗淋巴细胞球蛋白E .胸腺素3 •下列哪种叙述与胆碱受体激动剂不符A. 乙酰胆碱的乙酰基部分为芳环或较大分子量的基团时，转变为胆碱受体拮抗剂B. 乙酰胆碱的亚乙基桥上 ?位甲基取代， M 样作用大大增强，成为选择性 M 受体激动剂C. Carbachol 作用较乙酰胆碱强而持久D. Bethanechol Chloride 的S 构型异构体的活性大大高于 R 构型异构体E. 中枢 M 胆碱受体激动剂是潜在的抗老年痴呆药物 4 •下列有关乙酰胆碱酯酶抑制剂的叙述不正确的是A. Neostigmine Bromide 是可逆性乙酰胆碱酯酶抑制剂，其与 AChE 结合后形成的二甲氨基甲酰 化的酶结合物，水解释出原酶需要几分钟B. Neostigmine Bromide 结构中N, N -二甲氨基甲酸酯较 Physostigmine 结构中N-甲基氨基甲酸酯 稳定C. 中枢乙酰胆碱酯酶抑制剂可用于抗老年痴呆D. 经典的乙酰胆碱酯酶抑制剂结构中含有季铵碱阳离子、芳香环和氨基甲酸酯三部分E. 有机磷毒剂也是可逆性乙酰胆碱酯酶抑制剂 5 •下列叙述哪个不正确A. Scopolamine 分子中有三元氧环结构，使分子的亲脂性增强B. 托品酸结构中有一个手性碳原子， S 构型者具有左旋光性C. Atropine 水解产生托品和消旋托品酸D. 莨菪醇结构中有三个手性碳原子 C1、C3和C5,具有旋光性E. 山莨菪醇结构中有四个手性碳原子C1、C3、C5和C6,具有旋光性 6 •关于硫酸阿托品，下列说法不正确的是 A. 现可采用合成法制备 C.在碱性溶液较稳定E.制注射液时用适量氯化钠作稳定剂 7 •临床应用的阿托品是莨菪碱的 A. 右旋体 C.外消旋体 E.都在使用8•阿托品的特征定性鉴别反应是 A. 与 AgNO3 溶液反应 C.与CuSO4试液反应 E.紫脲酸胺反应选择题呫吨基的是9-胆碱受体拮抗剂分子中，具有M •下列合成9.A. Glycopyrr onium BromideB. Orphe nadr ineD. Ben actyz ine C. Propa ntheli ne BromideE. Pire nzep ine10Adrenaline不符的叙述是•下列与可激动饱和水溶液呈弱碱性和受体 A. B.R含邻苯二酚结构，易氧化变质构型为活性体，具右旋光性 D.-碳以C.E.直接受到单胺氧化酶和儿茶酚氧位甲基转移酶的代谢)-Ephedrine的结构是11.临床药用(OHOHNN B.A.(1S2S)(1S2ROO C. D. (1R2S(1R2R)上述四种的混合物E.受体拮抗剂的哪种结构类型12. Diphenhydramine属于组胺H1哌嗪类A.乙二胺类 B.D. C.丙胺类三环类氨基醚类E.13. 下列何者具有明显中枢镇静作用A. Chlorphe nami neB. Clemast ineC. AcrivastineD. LoratadineE. Cetirizi ne14. 若以下图代表局麻药的基本结构，则局麻作用最强的X为OCnNArXA. —O —B. —NH —C. —S—D. —CH2 —E. —NHNH —15. Lidocaine比Procaine作用时间长的主要原因是A. Procaine有芳香第一胺结构B. Procaine有酯基C. Lidocaine有酰胺结构D. Lidocaine的中间部分较Procaine短E.酰胺键比酯键不易水解16. 盐酸普鲁卡因最易溶于哪种试剂A.水B.酒精C.氯仿D.乙醚E.丙酮17. 盐酸鲁卡因因具有( )，故重氮化后与碱性B萘酚偶合后生成猩红色偶氮染料A.苯环B.伯氨基C.酯基D.芳伯氨基E.叔氨基18. 盐酸利多卡因的乙醇溶液加氯化钻试液即生成蓝绿色沉淀B. 结晶性沉淀A.D. 紫色沉淀 C.黄色沉淀E. 红色沉淀比较配伍题。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Product Name:
Tubastatin A Hydrochloride CAS No.:
1310693-92-5Cat. No.:
HY-13271MWt:
371.86Formula:
C20H22ClN3O2Purity :>98%
Solubility:Mechanisms:
Biological Activity:
References:
Caution: Not fully tested. For research purposes only
Medchemexpress LLC
[1]. Kyle V. Butler et al. Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6
Inhibitor, Tubastatin A J. Am. Chem. Soc., 2010, 132 (31), pp 10842-10846[2]. Constantin d'Ydewalle et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-
induced Charcot-Marie-Tooth disease Nature Medicine 17, 968-974 (2011)[3]. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP.,Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.,J Am Chem Soc. 2010 Aug
11;132(31):10842-6.
[4]. Ketene AN, Roberts PC, Shea AA, Schmelz EM, Agah M.,Actin filaments play a primary role for structural integrity and viscoelastic response in cells.,Integr Biol (Camb). 2012 May;4(5):540-9. Epub 2012 Mar 26.
Tubastatin A Hcl is a potent and selective HDAC6 inhibitor with IC50 of 15 nM; is selective (1000-fold more)
against all other isozymes except HDAC8 (57-fold more).
IC50 Value: 15 nM
Target: HDAC6in vitro: Tubastatin A is substantially selective for all 11 HDAC isoforms and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately 57-fold selectivity. In
homocysteic acid (HCA) induced neurodegeneration assays, Tubastatin A displays dose-dependent
protection against HCA-induced neuronal cell death starting at 5 μM with near complete protection at 10 μM.At 100 ng/mL Tubastatin A increases Foxp3+ T-regulatory cells (Tregs) suppression of T cell proliferation in vitro. Tubastatin A treatment in C2C12 cells would lead to myotube formation impairment when alpha-tubulin is hyperacetylated early in the myogenic process; however, m...
Pathways:Cell Cycle/DNA Damage; Target:HDAC Product Data Sheet
DMSO ≥70mg/mL Water <1.2mg/mL
Ethanol <0.8mg/mL
11 D e e r P a r k D r i v e , S u i t e 102D M o n m o u t h J u n c t i o n , N J 08852,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。